The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
本发明提供了一种N1-苯并[1,3]二噁英-5-基甲基-N2-取代双胍衍
生物(I)或其药学上可接受的盐,一种制备该衍
生物的方法以及包含该衍
生物作为活性成分的制药组合物。本发明的N1-苯并[1,3]二噁英-5-基甲基-N2-取代双胍衍
生物即使剂量减少,也能表现出改善血糖
水平和血脂
水平的效果,与传统药物相比具有更好的降糖和降脂作用,因此,它对于预防或治疗糖尿病、
胰岛素非依赖性糖尿病、肥胖症和动脉粥样硬化或P53
基因缺陷相关的癌症是有用的。